---
provider: openai
model: o3-deep-research-2025-06-26
cached: true
start_time: '2025-11-03T22:11:42.850413'
end_time: '2025-11-03T22:11:42.853221'
duration_seconds: 0.0
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: Q16586
  gene_symbol: SGCA
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    temperature: 0.1
    top_p: 1.0
citation_count: 116
---

## Question

# Gene Research for Functional Annotation

Please provide a comprehensive research report on the gene SGCA (Q16586) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function. 

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

# Introduction: The SGCA Gene and Protein Overview  
Alpha-sarcoglycan, encoded by the human **SGCA** gene (UniProt Q16586), is a transmembrane glycoprotein predominantly expressed in striated muscle ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=Summary%20This%20gene%20encodes%20a,provided%20by%20RefSeq)). It was originally identified as a 50 kDa dystrophin-associated glycoprotein (“adhalin”) in muscle cell membranes ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B1,deleterious%20polymorphisms%20may%20affect%20cysteine)). SGCA is one of four sarcoglycan subunits (α, β, γ, δ) that assemble into a tetrameric complex within the dystrophin-glycoprotein complex (DGC) of muscle fibers ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity)). This complex localizes at the sarcolemma (plasma membrane) of skeletal and cardiac muscle cells – notably concentrated at costameres, the membrane domains aligned with Z-discs ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more)). By virtue of its position in the DGC, alpha-sarcoglycan plays a crucial structural role in linking the intracellular cytoskeleton to the extracellular matrix and maintaining muscle fiber integrity ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=Summary%20This%20gene%20encodes%20a,provided%20by%20RefSeq)) ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity)). Mutations in SGCA cause limb-girdle muscular dystrophy type 2D (LGMD2D, also known as LGMDR3), an autosomal recessive muscle-wasting disease ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=which%20is%20critical%20to%20the,Multiple%20transcript%20variants)) ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycanopathies%20comprise%20four%20subtypes%20of,the%20genetically%20confirmed%20patients%20with)). In the sections below, we detail the function of alpha-sarcoglycan, the biological processes and pathways it influences, its cellular localization, and current research findings, with an emphasis on recent studies and expert analyses.

## Structural Role in Muscle Fiber Integrity  
Alpha-sarcoglycan’s primary function is as a **structural component** of the dystrophin-associated glycoprotein complex, which connects the internal actin cytoskeleton to the external basement membrane in muscle tissue ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity)). Together with β-, γ-, and δ-sarcoglycan, alpha-sarcoglycan forms a transmembrane subcomplex that stabilizes the DGC at the muscle membrane ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=Sarcoglycanopathies%20are%20a%20group%20of,or%20reduced%20concentration%20of%20the)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the)). During muscle contraction and stretch, this complex serves as a mechanical buffer or “shock absorber,” protecting the sarcolemmal membrane from stress-induced damage ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the)). In normal muscle, the sarcoglycan complex and dystrophin are enriched at costameres – periodic membrane complexes that anchor the contractile apparatus to the sarcolemma – thereby distributing contractile force laterally to the extracellular matrix ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more)). Alpha-sarcoglycan is a single-pass type I membrane protein with a large N-terminal extracellular domain (heavily N-glycosylated) and a short C-terminal cytosolic tail ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B1,deleterious%20polymorphisms%20may%20affect%20cysteine)). Beta-, gamma-, and delta-sarcoglycans, in contrast, are type II membrane glycoproteins with cytosolic N-termini ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=Shown%20is%20a%20schematic%20of,sarcoglycan.%20%28more)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B3)). Within the mature complex, β-sarcoglycan tightly associates with δ-sarcoglycan to form a core, which then recruits γ- and α-sarcoglycan ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=consists%20of%20four%20transmembrane%20glycoproteins,sarcoglycan%20complex%20undergoes%20chemical%20modifications)). Proper assembly of all four subunits is required for the complex’s stability and membrane targeting ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=for%20membrane%20integrity%20during%20muscle,Recent%20evidence%20shows%20that)). Indeed, a mutation in any one sarcoglycan gene often leads to loss or mislocalization of the entire complex at the sarcolemma ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=the%20sarcoglycan%20complex%20is%20of,This%20review%20summarises%20the)) ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=relaxation%20through%20association%20with%20the,1998%3B%20Lim%20and%20Campbell%2C%201998)). This “domino effect” occurs because misfolded sarcoglycan subunits are recognized by cellular quality-control pathways and degraded, and without all subunits present the complex cannot anchor in the membrane ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=the%20sarcoglycan%20complex%20is%20of,This%20review%20summarises%20the)).  

Functionally, the presence of alpha-sarcoglycan is critical for **maintaining membrane integrity** during muscle activity. In a healthy DGC, the sarcoglycan-sarcospan subcomplex helps stabilize α-dystroglycan (another DGC component) at the cell surface, reinforcing the link to the extracellular matrix protein laminin in the basal lamina ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3855351/#:~:text=Sarcospan%20is%20a%20component%20of,termini%20contribute%20to%20stability%20of)). Disruption of SGCA accordingly weakens this linkage. Both patient studies and animal models demonstrate the importance of SGCA for membrane stability: muscle biopsies from LGMD2D patients show a loss of the entire sarcoglycan complex and associated DGC components at the sarcolemma ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=1990%3B%20Chan%20et%20al,1998%3B%20Lim%20and%20Campbell%2C%201998)) ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=relaxation%20through%20association%20with%20the,1998%3B%20Lim%20and%20Campbell%2C%201998)), and mice engineered with SGCA knockout develop progressive muscular dystrophy with muscle fiber necrosis and membrane tears ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=interactions%20within%20the%20sarcoglycan%20complex,sarcoglycan%20protein%20has%20homology%20to)). Notably, the muscle pathology caused by SGCA deficiency closely resembles that seen in X-linked Duchenne muscular dystrophy (a dystrophin defect) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=disrupted%20and%20destabilized%20from%20the,nonmuscle%20cell%20and%20tissue%20types)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=sarcoglycan%20genes%2C%20%CE%B1%2C%20%CE%B2%2C%20%CE%B3,in%20the%20central%20and%20peripheral)), underscoring that the integrity of the dystrophin–sarcoglycan network is essential for resisting the mechanical stress of contraction. In skeletal muscle, loss of alpha-sarcoglycan also secondarily leads to mislocalization of other DGC-associated proteins such as neuronal nitric oxide synthase (nNOS) at the membrane ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/12409321/#:~:text=PubMed%20pubmed,Our%20data%20suggest%20that%20loss)), even if dystrophin itself is intact. This suggests the full sarcoglycan complex is required to organize and retain certain signaling proteins like nNOS at the sarcolemma, which in turn affects muscle physiology (e.g. nNOS-mediated blood flow regulation) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/12409321/#:~:text=PubMed%20pubmed,Our%20data%20suggest%20that%20loss)). Overall, alpha-sarcoglycan’s structural role is to ensure the DGC forms a robust bridge from the intracellular cytoskeleton (via dystrophin and F-actin) to the extracellular matrix (via dystroglycan and laminin), thereby **preserving muscle fiber integrity and functionality** ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the)). Consistent with this, the sarcoglycan complex has been shown to undergo mechanical strain-dependent changes – for example, it can be chemically modified in response to muscle activity – which hints at a role in **transducing mechanical signals** in addition to providing passive stability ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=integrated%2C%20the%20sarcoglycan%20complex%20plays,been%20established%20to%20study%20the)).  

## Enzymatic Activity: Ecto-ATPase Function  
Beyond its mechanical role, alpha-sarcoglycan has a noteworthy **enzymatic function** as an extracellular ATP-hydrolyzing enzyme (ecto-ATPase). Biochemical studies in the early 2000s revealed that the large extracellular domain of α-sarcoglycan binds ATP and can hydrolyze it, suggesting alpha-sarcoglycan is an ecto-nucleoside triphosphatase on the muscle cell surface ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=is%20an%20ATP,sarcoglycan)). **Sandonà et al. (2004)** provided definitive evidence for this enzymatic activity: muscle cells expressing alpha-sarcoglycan displayed significant Ca²⁺/Mg²⁺-dependent ATPase activity, which could be specifically inhibited by an antibody against α-sarcoglycan’s ATP-binding motif ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=Salviati%20%281999%29%20J,human%20embryonic%20kidney%20293%C2%A0cells%20were)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=cells%20exhibited%20a%20significant%20increase,of%20muscular%20dystrophy%20are%20discussed)). Expressing human SGCA in heterologous cells conferred the ability to hydrolyze extracellular ATP (and ADP) with substrate specificity (no activity on other nucleotides), a low-millimolar affinity, and sensitivity to classic ecto-ATPase inhibitors (suramin, reactive blue-2) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=cells%20exhibited%20a%20significant%20increase,of%20muscular%20dystrophy%20are%20discussed)). Approximately 25% of the total ecto-ATPase activity in differentiated muscle cells (C2C12 myotubes) was attributable to α-sarcoglycan, based on antibody inhibition experiments ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=enzyme.%20The%20appearance%20of%20%CE%B1,The%20enzyme%20had%20a%20substrate)). These findings establish alpha-sarcoglycan as a **Ca²⁺/Mg²⁺-dependent ecto-ATP diphosphohydrolase** (akin to cell-surface nucleotidases) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=specificity%20for%20ATP%20and%20ADP%2C,of%20muscular%20dystrophy%20are%20discussed)). In other words, the protein can cleave extracellular ATP (eATP) to ADP (and possibly further to AMP), thereby modulating the concentration of ATP available outside the muscle fiber. 

This enzymatic capability has important implications for **cell signaling and pathology**. Extracellular ATP is a known “danger signal” (DAMP) that, when released from injured or stressed cells, can activate purinergic receptors on muscle and immune cells, triggering inflammation, calcium influx, and cell damage ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=In%20muscular%20dystrophies%2C%20muscle%20membrane,sarcoglycanopathy)). Normally, the ecto-ATPase activity of alpha-sarcoglycan is thought to help regulate this signal by clearing ATP released during muscle activity or mild membrane stress ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=Accordingly%2C%20pharmacologic%20and%20genetic%20inhibition,show%20that%20in%C2%A0vivo%20blockade%20of)). In SGCA-deficient muscle (LGMD2D), however, this regulatory mechanism is lost – leading to accumulation of eATP and exaggerated purinergic signaling. A 2019 study showed that **alpha-sarcoglycanopathy muscles have a defect in ecto-ATPase activity** and suffer heightened damage from eATP: Sgca-null myotubes in culture were prone to apoptosis upon ATP exposure ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=autofluorescence.%20Single,Undergo%20Apoptosis%20on%20ATP%20Treatment)), and Sgca-deficient mice exhibited chronic immune cell infiltration and muscle fiber damage linked to persistent eATP signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=In%20muscular%20dystrophies%2C%20muscle%20membrane,sarcoglycanopathy)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=eATP%20effects%20may%20be%20further,the%20inflammatory%20features%20was%20associated)). The same study demonstrated that blocking purinergic P2X receptors in Sgca-null mice (using a broad-spectrum P2X antagonist) markedly reduced muscle inflammation and necrosis and improved muscle fiber survival and strength ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy)). Treated mice showed dampened immune responses and increased regulatory T-cell recruitment in muscle, ultimately **delaying dystrophy progression** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy)). These findings strongly suggest that alpha-sarcoglycan’s normal role includes **protecting muscle cells from aberrant extracellular ATP signaling** by degrading ATP at the cell surface ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=Accordingly%2C%20pharmacologic%20and%20genetic%20inhibition,sarcoglycan%E2%80%93null%20mice)). In summary, the SGCA gene product is not only a structural linker but also an enzyme that safeguards muscle tissue from an “ATP-driven” inflammatory cascade. This dual functionality highlights a unique aspect of alpha-sarcoglycan: it bridges mechanical and biochemical defense mechanisms in muscle. Notably, the ATP-binding domain of α-sarcoglycan shares homology with ecto-ATPases in other systems ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=noted%20rarely%20in%20human%20subjects,sarcoglycan.%5E%7B27)), aligning with its observed enzymatic profile. Current research continues to explore how loss of this ATPase function contributes to dystrophy pathology and whether enhancing alternative ATP-clearing pathways could ameliorate disease in SGCA patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy)).

## Localization and Biological Context  
In human tissues, SGCA expression is **highest in skeletal and cardiac muscle**, reflecting its central role in striated muscle function ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=Summary%20This%20gene%20encodes%20a,provided%20by%20RefSeq)) ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=delta,2005)). Within muscle fibers, alpha-sarcoglycan localizes to the sarcolemma – specifically at costameres and other membrane domains where the dystrophin-associated complex resides ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more)). Costameric localization means alpha-sarcoglycan is positioned at regular intervals along the muscle fiber, directly underlying the Z-lines of the contractile apparatus ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=like%20the%20DGC%2C%20is%20concentrated,cardiac%20muscle%2C%20titin%2C%20MLP%20and)). This strategic placement enables it to help anchor the muscle cell membrane to the extracellular matrix in coordination with dystrophin and integrins ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more)). Electron microscopy and immunofluorescence studies have shown the sarcoglycan subunits in a linear, periodic pattern on muscle cross-sections, consistent with costamere distribution ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more)). In addition to the sarcolemma, alpha-sarcoglycan (and associated complex members) are also present at the muscle **neuromuscular junction (NMJ)** – the synapse between motor neurons and muscle fibers. Developmental studies indicated that sarcoglycans concentrate at NMJs in a nerve-dependent manner ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11754441/#:~:text=Sarcoglycans%20are%20enriched%20at%20the,48.Massopust%20RT%2C%20Lee)), though their function at the synapse was not fully understood until recently.  

Outside of muscle, **alpha-sarcoglycan’s expression was long thought to be muscle-specific**, but newer data reveal broader, albeit lower-level, distribution. A comprehensive 2025 scoping review of sarcoglycans reported **low but significant expression of SGCA and other sarcoglycans in various non-muscle tissues** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=This%20scoping%20review%20explores%20the,cells%2C%20implicating%20their%20involvement%20in)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=highlights%20the%20widespread%20presence%20of,that%20they%20may%20contribute%20to)). For example, sarcoglycans have been detected in the brain (localized in a “spot-like” pattern in neurons and glial cells), in certain glands, adipose tissue, the oral mucosa, and even the retina ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=highlights%20the%20widespread%20presence%20of,These%20findings%20underscore%20the)). In these contexts, the sarcoglycan complex may contribute to cell membrane stability, cell–matrix adhesion, or signaling, analogous to its role in muscle ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SG%20subunits%20in%20neurons%20and,However)). In the central nervous system, the presence of alpha- and epsilon-sarcoglycan in neurons has been linked to organizing synapses and possibly modulating neurotransmission ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=structures%2C%20with%20distinct%20regional%20and,However)). Smooth muscle expresses an **alternative isoform, epsilon-sarcoglycan (SGCE)**, which is highly similar to alpha-sarcoglycan and can form a variant complex in vascular and visceral smooth muscle ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=Dystrophy%20and%20referred%20to%20as,has%20important%20roles%20in%20both)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B5)). Epsilon-sarcoglycan often substitutes for alpha-sarcoglycan in non-striated muscle tissues – for instance, vascular smooth muscle relies on SGCE such that SGCA mutations do not disrupt the vascular DGC ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=absent%20cardiac%20phenotype%20associated%20with,sarcoglycan.%2050)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=allele.)). This tissue specificity explains some clinical observations: patients with SGCA mutations (and Sgca-knockout mice) typically have skeletal muscle and mild cardiac involvement, but relatively preserved vascular and smooth muscle function ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=not%20associated%20with%20any%20muscle,sarcoglycan%20protein%20has%20homology%20to)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=allele.)). In fact, Sgca-null mice do not develop cardiomyopathy, likely because the vascular smooth muscle DGC remains intact (intact SGCE/epsilon-sarcoglycan in vessels may prevent the secondary vascular spasms and ischemic damage that occur in other sarcoglycan deficiencies) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=interactions%20within%20the%20sarcoglycan%20complex,this%20may%20be%20a%20feature)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=allele.)). By contrast, deficiencies in β- or δ-sarcoglycan affect both striated and smooth muscle complexes and often lead to significant cardiomyopathy ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B2,29%7D%20Notably%2C%20the%20smooth%20muscle)) ([www.ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B4)). Thus, alpha-sarcoglycan’s **physiological role is most pronounced in skeletal muscle and heart**, while other tissues have compensatory isoforms or lower demands for this protein. Nonetheless, the emerging evidence of SGCA in non-muscle cells suggests the protein could have **additional roles in cellular adhesion or signaling beyond muscle**, a subject of ongoing research ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SG%20subunits%20in%20neurons%20and,However)). 

## Signaling Interactions and Pathways  
Alpha-sarcoglycan, through the DGC, is part of a larger network that integrates structural integrity with cell signaling pathways in muscle. The DGC not only fortifies the membrane but also serves as a scaffold for signaling molecules. For instance, components of the DGC (dystrophin and syntrophins) normally anchor neuronal nitric oxide synthase (nNOS) at the sarcolemma, facilitating activity-dependent nitric oxide signaling for blood vessel dilation during muscle use. As noted, the sarcoglycan complex is required for stable nNOS localization; *in vivo* studies show that partial loss of the complex (even with dystrophin present) can displace nNOS from the membrane ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/12409321/#:~:text=PubMed%20pubmed,Our%20data%20suggest%20that%20loss)), which may contribute to muscle fatigue and ischemia in dystrophic muscles. Additionally, the sarcoglycans themselves appear to partake in **mechanotransduction signaling**. A 2016 review highlighted that the sarcoglycan complex undergoes post-translational modifications (such as phosphorylation) in response to muscle contraction, implying that it can transmit mechanical signals inward to influence cellular processes ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=integrated%2C%20the%20sarcoglycan%20complex%20plays,been%20established%20to%20study%20the)). This could activate downstream pathways related to muscle growth or repair in response to load, although the precise signaling cascades remain under investigation. Interestingly, α- and β-sarcoglycan each have short cytoplasmic tails that could interact with signaling or adapter proteins. While no enzymatic signaling domain is present, these cytosolic tails might recruit kinases or modulate membrane microdomain organization during muscle activity ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the)). 

A **recent discovery** expanded alpha-sarcoglycan’s role into the realm of synapse biology. In 2018, Zhang et al. reported a novel function for SGCA at the neuromuscular junction: **stabilization of LRP4**, a key postsynaptic receptor in the agrin-MuSK signaling pathway ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice)). LRP4 (Low-density lipoprotein receptor-related protein 4) is essential for NMJ formation and maintenance, as it binds neural agrin and activates MuSK to cluster acetylcholine receptors. In aged mice, LRP4 protein levels decline (due to increased ubiquitination and degradation), contributing to synaptic fragmentation and muscle denervation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=During%20aging%2C%20acetylcholine%20receptor%20,LRP4%20degradation%20as%20a%20mechanism)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=suggesting%20compromised%20agrin,serves%20as%20a%20pathological%20mechanism)). Zhang’s team found that alpha-sarcoglycan physically interacts with LRP4 in muscle, and this interaction helps prevent LRP4 degradation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice)). Augmenting SGCA expression in aged muscle (via AAV9 gene delivery) led to higher LRP4 levels, reduced NMJ deterioration, and improved neuromuscular transmission ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice)). These results identify SGCA as a positive regulator of the **agrin-LRP4-MuSK pathway**, suggesting that the sarcoglycan complex contributes not just to muscle fiber stability but also to the stability of synaptic connections in muscle. This is an example of how the sarcoglycan complex might influence cell–cell communication and signaling: by maintaining the localization or half-life of membrane receptors like LRP4. It also aligns with evidence that sarcoglycans are enriched at the NMJ during development ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11754441/#:~:text=Sarcoglycans%20are%20enriched%20at%20the,48.Massopust%20RT%2C%20Lee)). Thus, **SGCA lies at the intersection of structural and signaling pathways** – it supports the physical muscle architecture and modulates signaling events (mechanotransduction, synaptic maintenance, and purinergic signaling as discussed) that are crucial for muscle function and homeostasis. 

## Clinical Significance: SGCA in Muscular Dystrophy  
**Mutations in SGCA cause limb-girdle muscular dystrophy type 2D (LGMD2D)**, one of the autosomal recessive sarcoglycanopathy subtypes. Patients typically present in childhood (often between ages 2–10) with progressive weakness of the proximal limb muscles (shoulder and hip girdles) ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=The%20sarcoglycan%20genes%20were%20identified,milder%20cases%2C%20in%20which%20patients)). The disease is characterized by muscle fiber degeneration, elevated serum creatine kinase, and replacement of muscle by fat and connective tissue over time. Most individuals with SGCA mutations lose independent ambulation in their teens or early adulthood, though there is a spectrum of severity ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=The%20sarcoglycan%20genes%20were%20identified,milder%20cases%2C%20in%20which%20patients)). Some milder cases have been documented where patients remain ambulatory into middle age ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=patients%20develop%20progressive%20proximal%20muscle,Melacini%20et%20al)). Cardiac and respiratory muscle involvement in SGCA-LGMD can occur but is somewhat less frequent or delayed compared to other LGMD forms ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=sarcoglycanopathies%20are%20severe%20disorders%20characterized,of%20protein%20expression%20cause%20a)). Notably, an international cohort study (439 patients across Europe with sarcoglycanopathies, published 2020) found that **alpha-sarcoglycan deficiency (LGMDR3)** patients had later onset and slower disease progression on average than those with β-, γ-, or δ-sarcoglycan defects ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=clinical%20data%20were%20collected%20for,T.%20We)). Among 396 analyzed cases in that study, 159 had SGCA mutations, making it one of the more common sarcoglycanopathies ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=clinical%20data%20were%20collected%20for,525delT%20or)). About 60% of SGCA-LGMD patients in the European cohort carried one of three recurrent missense mutations (p.R77C, p.C245S, or p.R281C), reflecting founder effects in certain populations ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=the%20analysis%20because%20of%20insufficient,T.%20We)). Genotype–phenotype analysis indicates that **null or severe missense mutations (causing little to no alpha-sarcoglycan at the membrane) result in earlier loss of ambulation**, whereas hypomorphic mutations that allow some residual protein (≥30% of normal levels) correlate with milder progression ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sixty%20per%20cent%20of%20LGMDR3,our%20knowledge%20about%20these%20extremely)). As with other sarcoglycanopathies, SGCA mutations typically cause misfolding of the protein that triggers its retention and degradation via the endoplasmic reticulum quality control system ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=the%20sarcoglycan%20complex%20is%20of,This%20review%20summarises%20the)). Consequently, even missense mutations can behave like null alleles due to the absence of the protein at the muscle membrane. Immunohistochemistry on patient biopsies often shows **complete loss of alpha-sarcoglycan, and secondary loss of the other sarcoglycans** in the sarcolemma ([academic.oup.com](https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=relaxation%20through%20association%20with%20the,1998%3B%20Lim%20and%20Campbell%2C%201998)). This loss of the entire sarcoglycan complex is a diagnostic hallmark of sarcoglycanopathy, distinguishing it from dystrophinopathies or other muscular dystrophies. 

In terms of pathology, SGCA deficiency leads to a fragile muscle membrane that is susceptible to contraction-induced tearing. Repeated cycles of muscle fiber damage and inefficient repair lead to chronic inflammation and fibrosis in muscle tissue. As discussed, the **absence of alpha-sarcoglycan also means a loss of its ecto-ATPase protective function**, which likely exacerbates inflammation via uncontrolled extracellular ATP signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=Accordingly%2C%20pharmacologic%20and%20genetic%20inhibition,sarcoglycan%E2%80%93null%20mice)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy)). In a mouse model of SGCA-deficient muscular dystrophy, investigators observed that blocking the ATP/P2X7 receptor pathway (using oxidized ATP or other antagonists) significantly reduced muscle inflammation and decreased fibrosis ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy)). This suggests that therapies targeting the downstream effects of SGCA loss (like excessive purinergic signaling or fibrogenesis) can modify disease severity. For example, a 2022 study tested **nintedanib**, an anti-fibrotic tyrosine kinase inhibitor, in Sgca-null mice and found it reduced muscle fibrosis and improved muscle function compared to untreated dystrophic mice ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=strength%20significantly%20improved%20after%20treatment,percentage%20eMyHC%20positive%20fibers%20over)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=Figure%202)). The treated mice showed decreased collagen deposition and a lower number of pro-fibrotic fibro/adipogenic progenitor cells in muscle ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=Nintedanib%20reduces%20muscle%20fibrosis%20in,NT)) ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=shown,Scale%20bar%20%3D%20200%20%CE%BCm)), correlating with stronger muscle force. While such adjunct therapies do not address the root cause (the missing SGCA protein), they highlight the multi-faceted pathology of SGCA deficiency and offer bridges to improve muscle outcomes while gene-specific treatments are developed.

## Therapeutic Developments and Research Frontiers  
**Restoring alpha-sarcoglycan function** is the ultimate goal for treating LGMD2D. Because SGCA mutations cause a loss of function, gene replacement therapy has been a major area of research. Early proof-of-concept studies in the mid-2000s showed that delivering a normal SGCA gene to dystrophic muscle can reconstitute the sarcoglycan complex and improve muscle pathology in animal models ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Alpha,and%20persistence%20of%20gene%20expression)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Methods)). This led to the first-in-human trials of **AAV-mediated SGCA gene therapy**. In a landmark Phase 1 trial reported by Mendell et al. (2009), an adeno-associated virus serotype 1 carrying the human SGCA gene (rAAV1.tMCK.hSGCA) was injected into a foot muscle (extensor digitorum brevis) of LGMD2D patients ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Methods)). The results demonstrated **successful local transgene expression and protein restoration**: muscle biopsies after treatment showed that α-sarcoglycan mRNA and protein increased ~4–5-fold compared to control muscles, and the full sarcoglycan complex (α/β/γ/δ) was reassembled at the membrane in the treated site ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Results)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=No%20adverse%20events%20were%20encountered,capsid%20specific%20T%20cells%20by)). Importantly, muscle fiber size increased in treated muscles, and there were no serious adverse events aside from transient, self-resolving inflammation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=No%20adverse%20events%20were%20encountered,capsid%20specific%20T%20cells%20by)). Low-level immune responses to the AAV capsid were observed in some patients, but a short prednisone regimen was used to mitigate immunity ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=transfer%20without%20further%20immune%20suppression)). A follow-up trial in 2010 achieved **sustained SGCA expression for at least 6 months** in two patients, with continued presence of the protein and complex at the sarcolemma over time ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2970162/#:~:text=Persistent%20alpha,This%20was%20in)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2970162/#:~:text=The%20findings%20of%20this%20gene,reversal%20of%20disease%20was%20displayed)). These trials provided a critical proof that gene therapy can stably deliver the missing protein to patient muscles and potentially slow or reverse disease features ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2970162/#:~:text=The%20findings%20of%20this%20gene,reversal%20of%20disease%20was%20displayed)). As a result, larger-scale trials are in development. (One challenge for limb-girdle MD gene therapy is body-wide delivery; recent preclinical work on systemic AAV delivery for related sarcoglycan deficiencies, such as γ-sarcoglycan, has shown dose-dependent functional improvements in mice ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929442/#:~:text=correction%20of%20muscle%20deficits%20in,1%7D%2C%20Stephen%20H%20Baine)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9929442/#:~:text=Skip%20to%20main%20content%20Mol,1%7D%2C%20Stephen%20H%20Baine)), offering hope that whole-body muscle transduction is achievable in the future.)

Another emerging approach is **gene editing**. In 2021, Escobar et al. applied base-editing technology to correct a prevalent SGCA mutation in patient-derived muscle stem cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8262330/#:~:text=muscle%20diseases%20has%20not%20yet,90)). They targeted the c.157G>A mutation (which causes aberrant splicing and loss of α-sarcoglycan) using an adenine base editor delivered to the cells. Impressively, they achieved over 90% precise correction of the mutation in vitro, which restored normal splicing and SGCA expression in these cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8262330/#:~:text=onset%2C%20severe%2C%20and%20rapidly%20progressive,90)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC8262330/#:~:text=affecting%20the%20limbs%2C%20respiratory%20muscles%2C,90)). This study (published May 24, 2021 in *JCI Insight*) provides a proof-of-principle that patient muscle stem cells can be genetically repaired ex vivo and could potentially be reimplanted as a personalized cell therapy. While still far from clinical use, such gene editing strategies – including CRISPR/Cas9 approaches – are being actively explored to treat muscular dystrophies at the DNA level. Beyond gene replacement or editing, researchers are also investigating pharmacological methods to **enhance the folding and trafficking of mutant alpha-sarcoglycan**. Many missense mutations yield proteins that are functional if they reach the membrane, but are prematurely destroyed by the cell’s quality control. Chemical chaperones or proteostasis regulators might promote the proper folding or escape of these mutant proteins from the ER. In fact, pharmacological modulation of the ER quality control has been proposed as a therapy: assisting mutant sarcoglycans to fold and travel to the plasma membrane could “rescue” their function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=through%20the%20cell%27s%20quality%20control,therapy%20of%20these%20genetic%20disorders)). For example, small molecules that inhibit ER calcium channels or the proteasome have shown partial restoration of sarcoglycan complex in cell models of sarcoglycanopathy ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=through%20the%20cell%27s%20quality%20control,therapy%20of%20these%20genetic%20disorders)). Though no such drug is yet in routine use, the concept underscores a broader therapeutic strategy complementing gene therapy. 

In summary, **SGCA (alpha-sarcoglycan)** encodes a muscle-membrane protein that is crucial for the structural stability of muscle fibers and also performs a biochemical role in regulating extracellular ATP signaling. Its dysfunction leads to a specific form of muscular dystrophy with significant morbidity. Ongoing research and clinical trials – including gene therapy vectors, gene editing techniques, and adjunct medications – are actively pursuing ways to restore alpha-sarcoglycan’s function or mitigate the downstream damage caused by its loss. The convergence of structural biology, enzymology, and gene therapy in the study of SGCA exemplifies the modern approach to functional gene annotation: understanding a gene product’s **molecular role, interaction networks, and pathology** in order to devise targeted interventions. Continued insights from primary research (e.g. novel binding partners like LRP4 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice))) and authoritative reviews (e.g. on sarcoglycan complex function ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the))) will guide the development of effective therapies for conditions like LGMD2D, where alpha-sarcoglycan is at the center of muscle fiber viability. 

**References:** (Key references are provided inline above, with publication dates and sources for verification. Recent sources from 2018–2025 have been prioritized to reflect current understanding.)

## Citations

1. AnnotationURLCitation(end_index=362, start_index=200, title='SGCA sarcoglycan alpha [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=Summary%20This%20gene%20encodes%20a,provided%20by%20RefSeq')
2. AnnotationURLCitation(end_index=615, start_index=477, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B1,deleterious%20polymorphisms%20may%20affect%20cysteine')
3. AnnotationURLCitation(end_index=964, start_index=777, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity')
4. AnnotationURLCitation(end_index=1273, start_index=1142, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more')
5. AnnotationURLCitation(end_index=1634, start_index=1472, title='SGCA sarcoglycan alpha [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=Summary%20This%20gene%20encodes%20a,provided%20by%20RefSeq')
6. AnnotationURLCitation(end_index=1822, start_index=1635, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity')
7. AnnotationURLCitation(end_index=2134, start_index=1965, title='SGCA sarcoglycan alpha [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=which%20is%20critical%20to%20the,Multiple%20transcript%20variants')
8. AnnotationURLCitation(end_index=2324, start_index=2135, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycanopathies%20comprise%20four%20subtypes%20of,the%20genetically%20confirmed%20patients%20with')
9. AnnotationURLCitation(end_index=3015, start_index=2828, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity')
10. AnnotationURLCitation(end_index=3322, start_index=3156, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=Sarcoglycanopathies%20are%20a%20group%20of,or%20reduced%20concentration%20of%20the')
11. AnnotationURLCitation(end_index=3490, start_index=3323, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the')
12. AnnotationURLCitation(end_index=3825, start_index=3658, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the')
13. AnnotationURLCitation(end_index=4207, start_index=4076, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more')
14. AnnotationURLCitation(end_index=4514, start_index=4376, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B1,deleterious%20polymorphisms%20may%20affect%20cysteine')
15. AnnotationURLCitation(end_index=4760, start_index=4628, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=Shown%20is%20a%20schematic%20of,sarcoglycan.%20%28more')
16. AnnotationURLCitation(end_index=4845, start_index=4761, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B3')
17. AnnotationURLCitation(end_index=5175, start_index=4983, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=consists%20of%20four%20transmembrane%20glycoproteins,sarcoglycan%20complex%20undergoes%20chemical%20modifications')
18. AnnotationURLCitation(end_index=5438, start_index=5277, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=for%20membrane%20integrity%20during%20muscle,Recent%20evidence%20shows%20that')
19. AnnotationURLCitation(end_index=5720, start_index=5566, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=the%20sarcoglycan%20complex%20is%20of,This%20review%20summarises%20the')
20. AnnotationURLCitation(end_index=5897, start_index=5721, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=relaxation%20through%20association%20with%20the,1998%3B%20Lim%20and%20Campbell%2C%201998')
21. AnnotationURLCitation(end_index=6261, start_index=6107, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=the%20sarcoglycan%20complex%20is%20of,This%20review%20summarises%20the')
22. AnnotationURLCitation(end_index=6767, start_index=6605, title='Structural and Functional Analysis of the Sarcoglycan-Sarcospan Subcomplex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3855351/#:~:text=Sarcospan%20is%20a%20component%20of,termini%20contribute%20to%20stability%20of')
23. AnnotationURLCitation(end_index=7204, start_index=7051, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=1990%3B%20Chan%20et%20al,1998%3B%20Lim%20and%20Campbell%2C%201998')
24. AnnotationURLCitation(end_index=7381, start_index=7205, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=relaxation%20through%20association%20with%20the,1998%3B%20Lim%20and%20Campbell%2C%201998')
25. AnnotationURLCitation(end_index=7680, start_index=7507, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=interactions%20within%20the%20sarcoglycan%20complex,sarcoglycan%20protein%20has%20homology%20to')
26. AnnotationURLCitation(end_index=7989, start_index=7828, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=disrupted%20and%20destabilized%20from%20the,nonmuscle%20cell%20and%20tissue%20types')
27. AnnotationURLCitation(end_index=8161, start_index=7990, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=sarcoglycan%20genes%2C%20%CE%B1%2C%20%CE%B2%2C%20%CE%B3,in%20the%20central%20and%20peripheral')
28. AnnotationURLCitation(end_index=8610, start_index=8481, title='Loss of sarcolemma nNOS in sarcoglycan-deficient muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12409321/#:~:text=PubMed%20pubmed,Our%20data%20suggest%20that%20loss')
29. AnnotationURLCitation(end_index=8995, start_index=8866, title='Loss of sarcolemma nNOS in sarcoglycan-deficient muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12409321/#:~:text=PubMed%20pubmed,Our%20data%20suggest%20that%20loss')
30. AnnotationURLCitation(end_index=9461, start_index=9274, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sarcoglycans%20are%20transmembrane%20glycoproteins%20that,loss%20of%20muscle%20membrane%20integrity')
31. AnnotationURLCitation(end_index=9629, start_index=9462, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the')
32. AnnotationURLCitation(end_index=10088, start_index=9920, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=integrated%2C%20the%20sarcoglycan%20complex%20plays,been%20established%20to%20study%20the')
33. AnnotationURLCitation(end_index=10618, start_index=10509, title='Characterization of the ATP-hydrolysing activity of α-sarcoglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=is%20an%20ATP,sarcoglycan')
34. AnnotationURLCitation(end_index=11060, start_index=10900, title='Characterization of the ATP-hydrolysing activity of α-sarcoglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=Salviati%20%281999%29%20J,human%20embryonic%20kidney%20293%C2%A0cells%20were')
35. AnnotationURLCitation(end_index=11235, start_index=11061, title='Characterization of the ATP-hydrolysing activity of α-sarcoglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=cells%20exhibited%20a%20significant%20increase,of%20muscular%20dystrophy%20are%20discussed')
36. AnnotationURLCitation(end_index=11685, start_index=11511, title='Characterization of the ATP-hydrolysing activity of α-sarcoglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=cells%20exhibited%20a%20significant%20increase,of%20muscular%20dystrophy%20are%20discussed')
37. AnnotationURLCitation(end_index=12022, start_index=11863, title='Characterization of the ATP-hydrolysing activity of α-sarcoglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=enzyme.%20The%20appearance%20of%20%CE%B1,The%20enzyme%20had%20a%20substrate')
38. AnnotationURLCitation(end_index=12327, start_index=12161, title='Characterization of the ATP-hydrolysing activity of α-sarcoglycan - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC1133767/#:~:text=specificity%20for%20ATP%20and%20ADP%2C,of%20muscular%20dystrophy%20are%20discussed')
39. AnnotationURLCitation(end_index=12980, start_index=12827, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=In%20muscular%20dystrophies%2C%20muscle%20membrane,sarcoglycanopathy')
40. AnnotationURLCitation(end_index=13337, start_index=13150, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=Accordingly%2C%20pharmacologic%20and%20genetic%20inhibition,show%20that%20in%C2%A0vivo%20blockade%20of')
41. AnnotationURLCitation(end_index=13854, start_index=13700, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=autofluorescence.%20Single,Undergo%20Apoptosis%20on%20ATP%20Treatment')
42. AnnotationURLCitation(end_index=14136, start_index=13983, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=In%20muscular%20dystrophies%2C%20muscle%20membrane,sarcoglycanopathy')
43. AnnotationURLCitation(end_index=14306, start_index=14137, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=eATP%20effects%20may%20be%20further,the%20inflammatory%20features%20was%20associated')
44. AnnotationURLCitation(end_index=14685, start_index=14531, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy')
45. AnnotationURLCitation(end_index=14988, start_index=14834, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy')
46. AnnotationURLCitation(end_index=15351, start_index=15175, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=Accordingly%2C%20pharmacologic%20and%20genetic%20inhibition,sarcoglycan%E2%80%93null%20mice')
47. AnnotationURLCitation(end_index=15889, start_index=15752, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=noted%20rarely%20in%20human%20subjects,sarcoglycan.%5E%7B27')
48. AnnotationURLCitation(end_index=16295, start_index=16141, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy')
49. AnnotationURLCitation(end_index=16638, start_index=16476, title='SGCA sarcoglycan alpha [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=6442#:~:text=Summary%20This%20gene%20encodes%20a,provided%20by%20RefSeq')
50. AnnotationURLCitation(end_index=16737, start_index=16639, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=delta,2005')
51. AnnotationURLCitation(end_index=17042, start_index=16911, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more')
52. AnnotationURLCitation(end_index=17372, start_index=17212, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=like%20the%20DGC%2C%20is%20concentrated,cardiac%20muscle%2C%20titin%2C%20MLP%20and')
53. AnnotationURLCitation(end_index=17655, start_index=17524, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more')
54. AnnotationURLCitation(end_index=17970, start_index=17839, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=DGC%20elements%20are%20concentrated%20in,In%20%28more')
55. AnnotationURLCitation(end_index=18423, start_index=18271, title='Sarcoglycans are enriched at the neuromuscular junction in a nerve-dependent manner - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11754441/#:~:text=Sarcoglycans%20are%20enriched%20at%20the,48.Massopust%20RT%2C%20Lee')
56. AnnotationURLCitation(end_index=18997, start_index=18822, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=This%20scoping%20review%20explores%20the,cells%2C%20implicating%20their%20involvement%20in')
57. AnnotationURLCitation(end_index=19164, start_index=18998, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=highlights%20the%20widespread%20presence%20of,that%20they%20may%20contribute%20to')
58. AnnotationURLCitation(end_index=19527, start_index=19361, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=highlights%20the%20widespread%20presence%20of,These%20findings%20underscore%20the')
59. AnnotationURLCitation(end_index=19810, start_index=19683, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SG%20subunits%20in%20neurons%20and,However')
60. AnnotationURLCitation(end_index=20123, start_index=19982, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=structures%2C%20with%20distinct%20regional%20and,However')
61. AnnotationURLCitation(end_index=20470, start_index=20320, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=Dystrophy%20and%20referred%20to%20as,has%20important%20roles%20in%20both')
62. AnnotationURLCitation(end_index=20555, start_index=20471, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B5')
63. AnnotationURLCitation(end_index=20903, start_index=20759, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=absent%20cardiac%20phenotype%20associated%20with,sarcoglycan.%2050')
64. AnnotationURLCitation(end_index=20989, start_index=20904, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=allele.')
65. AnnotationURLCitation(end_index=21388, start_index=21228, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=not%20associated%20with%20any%20muscle,sarcoglycan%20protein%20has%20homology%20to')
66. AnnotationURLCitation(end_index=21474, start_index=21389, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=allele.')
67. AnnotationURLCitation(end_index=21903, start_index=21744, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=interactions%20within%20the%20sarcoglycan%20complex,this%20may%20be%20a%20feature')
68. AnnotationURLCitation(end_index=21989, start_index=21904, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=allele.')
69. AnnotationURLCitation(end_index=22261, start_index=22134, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B2,29%7D%20Notably%2C%20the%20smooth%20muscle')
70. AnnotationURLCitation(end_index=22346, start_index=22262, title='The Sarcoglycans - Madame Curie Bioscience Database - NCBI Bookshelf', type='url_citation', url='https://www.ncbi.nlm.nih.gov/books/NBK6317/#:~:text=%CE%B4')
71. AnnotationURLCitation(end_index=22850, start_index=22723, title='A Scoping Review of Sarcoglycan Expression in Non-Muscle Organs: Beyond Muscles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12294094/#:~:text=SG%20subunits%20in%20neurons%20and,However')
72. AnnotationURLCitation(end_index=23697, start_index=23568, title='Loss of sarcolemma nNOS in sarcoglycan-deficient muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/12409321/#:~:text=PubMed%20pubmed,Our%20data%20suggest%20that%20loss')
73. AnnotationURLCitation(end_index=24287, start_index=24119, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=integrated%2C%20the%20sarcoglycan%20complex%20plays,been%20established%20to%20study%20the')
74. AnnotationURLCitation(end_index=24907, start_index=24740, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the')
75. AnnotationURLCitation(end_index=25321, start_index=25182, title='Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice')
76. AnnotationURLCitation(end_index=25835, start_index=25664, title='Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=During%20aging%2C%20acetylcholine%20receptor%20,LRP4%20degradation%20as%20a%20mechanism')
77. AnnotationURLCitation(end_index=25995, start_index=25836, title='Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=suggesting%20compromised%20agrin,serves%20as%20a%20pathological%20mechanism')
78. AnnotationURLCitation(end_index=26272, start_index=26133, title='Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice')
79. AnnotationURLCitation(end_index=26574, start_index=26435, title='Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice')
80. AnnotationURLCitation(end_index=27237, start_index=27085, title='Sarcoglycans are enriched at the neuromuscular junction in a nerve-dependent manner - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11754441/#:~:text=Sarcoglycans%20are%20enriched%20at%20the,48.Massopust%20RT%2C%20Lee')
81. AnnotationURLCitation(end_index=28047, start_index=27872, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=The%20sarcoglycan%20genes%20were%20identified,milder%20cases%2C%20in%20which%20patients')
82. AnnotationURLCitation(end_index=28520, start_index=28345, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=The%20sarcoglycan%20genes%20were%20identified,milder%20cases%2C%20in%20which%20patients')
83. AnnotationURLCitation(end_index=28769, start_index=28610, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=patients%20develop%20progressive%20proximal%20muscle,Melacini%20et%20al')
84. AnnotationURLCitation(end_index=29095, start_index=28907, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=sarcoglycanopathies%20are%20severe%20disorders%20characterized,of%20protein%20expression%20cause%20a')
85. AnnotationURLCitation(end_index=29511, start_index=29375, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=clinical%20data%20were%20collected%20for,T.%20We')
86. AnnotationURLCitation(end_index=29771, start_index=29630, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=clinical%20data%20were%20collected%20for,525delT%20or')
87. AnnotationURLCitation(end_index=30099, start_index=29959, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=the%20analysis%20because%20of%20insufficient,T.%20We')
88. AnnotationURLCitation(end_index=30562, start_index=30398, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=Sixty%20per%20cent%20of%20LGMDR3,our%20knowledge%20about%20these%20extremely')
89. AnnotationURLCitation(end_index=30907, start_index=30753, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=the%20sarcoglycan%20complex%20is%20of,This%20review%20summarises%20the')
90. AnnotationURLCitation(end_index=31366, start_index=31190, title='New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy | Brain | Oxford Academic', type='url_citation', url='https://academic.oup.com/brain/article/143/9/2696/5900350#:~:text=relaxation%20through%20association%20with%20the,1998%3B%20Lim%20and%20Campbell%2C%201998')
91. AnnotationURLCitation(end_index=32150, start_index=31974, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=Accordingly%2C%20pharmacologic%20and%20genetic%20inhibition,sarcoglycan%E2%80%93null%20mice')
92. AnnotationURLCitation(end_index=32305, start_index=32151, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy')
93. AnnotationURLCitation(end_index=32690, start_index=32536, title='The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan–Deficient Muscular Dystrophy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC12179516/#:~:text=the%C2%A0eATP%2FP2X%20purinergic%20pathway%20by%20a,sarcoglycanopathy')
94. AnnotationURLCitation(end_index=33245, start_index=33065, title='Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=strength%20significantly%20improved%20after%20treatment,percentage%20eMyHC%20positive%20fibers%20over')
95. AnnotationURLCitation(end_index=33335, start_index=33246, title='Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=Figure%202')
96. AnnotationURLCitation(end_index=33597, start_index=33470, title='Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=Nintedanib%20reduces%20muscle%20fibrosis%20in,NT')
97. AnnotationURLCitation(end_index=33716, start_index=33598, title='Nintedanib Reduces Muscle Fibrosis and Improves Muscle Function of the Alpha-Sarcoglycan-Deficient Mice - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/36289891/#:~:text=shown,Scale%20bar%20%3D%20200%20%CE%BCm')
98. AnnotationURLCitation(end_index=34574, start_index=34442, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Alpha,and%20persistence%20of%20gene%20expression')
99. AnnotationURLCitation(end_index=34666, start_index=34575, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Methods')
100. AnnotationURLCitation(end_index=35063, start_index=34972, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Methods')
101. AnnotationURLCitation(end_index=35467, start_index=35376, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=Results')
102. AnnotationURLCitation(end_index=35629, start_index=35468, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=No%20adverse%20events%20were%20encountered,capsid%20specific%20T%20cells%20by')
103. AnnotationURLCitation(end_index=35944, start_index=35783, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=No%20adverse%20events%20were%20encountered,capsid%20specific%20T%20cells%20by')
104. AnnotationURLCitation(end_index=36219, start_index=36084, title='LGMD 2D gene therapy restores alpha-sarcoglycan and associated proteins - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6014624/#:~:text=transfer%20without%20further%20immune%20suppression')
105. AnnotationURLCitation(end_index=36522, start_index=36404, title='Sustained alpha-sarcoglycan gene expression following gene transfer in LGMD2D - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970162/#:~:text=Persistent%20alpha,This%20was%20in')
106. AnnotationURLCitation(end_index=36682, start_index=36523, title='Sustained alpha-sarcoglycan gene expression following gene transfer in LGMD2D - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970162/#:~:text=The%20findings%20of%20this%20gene,reversal%20of%20disease%20was%20displayed')
107. AnnotationURLCitation(end_index=37007, start_index=36848, title='Sustained alpha-sarcoglycan gene expression following gene transfer in LGMD2D - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2970162/#:~:text=The%20findings%20of%20this%20gene,reversal%20of%20disease%20was%20displayed')
108. AnnotationURLCitation(end_index=37453, start_index=37299, title='Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9929442/#:~:text=correction%20of%20muscle%20deficits%20in,1%7D%2C%20Stephen%20H%20Baine')
109. AnnotationURLCitation(end_index=37600, start_index=37454, title='Systemic γ-sarcoglycan AAV gene transfer results in dose-dependent correction of muscle deficits in the LGMD 2C/R5 mouse model - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9929442/#:~:text=Skip%20to%20main%20content%20Mol,1%7D%2C%20Stephen%20H%20Baine')
110. AnnotationURLCitation(end_index=37982, start_index=37860, title='Base editing repairs an SGCA mutation in human primary muscle stem cells - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8262330/#:~:text=muscle%20diseases%20has%20not%20yet,90')
111. AnnotationURLCitation(end_index=38417, start_index=38280, title='Base editing repairs an SGCA mutation in human primary muscle stem cells - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8262330/#:~:text=onset%2C%20severe%2C%20and%20rapidly%20progressive,90')
112. AnnotationURLCitation(end_index=38558, start_index=38418, title='Base editing repairs an SGCA mutation in human primary muscle stem cells - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8262330/#:~:text=affecting%20the%20limbs%2C%20respiratory%20muscles%2C,90')
113. AnnotationURLCitation(end_index=39766, start_index=39595, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=through%20the%20cell%27s%20quality%20control,therapy%20of%20these%20genetic%20disorders')
114. AnnotationURLCitation(end_index=40109, start_index=39938, title='Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3279956/#:~:text=through%20the%20cell%27s%20quality%20control,therapy%20of%20these%20genetic%20disorders')
115. AnnotationURLCitation(end_index=41291, start_index=41152, title='Sarcoglycan Alpha Mitigates Neuromuscular Junction Decline in Aged Mice by Stabilizing LRP4 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6181315/#:~:text=for%20reduced%20LRP4,NMJ%20stability%20in%20aged%20mice')
116. AnnotationURLCitation(end_index=41524, start_index=41357, title='The sarcoglycan complex in skeletal muscle - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/26709803/#:~:text=sarcoglycan%20complex%20binds%20other%20components,been%20established%20to%20study%20the')